ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Incorporated (OTCBB: INSV) announced today that it will report financial results for the fourth quarter and year ended December 31, 2010 on Thursday, February 24, 2011.
Company management will host a conference call that day beginning at 4:30 p.m. ET/1:30 p.m. PT to review recent accomplishments, upcoming milestones and to discuss quarterly and full year 2010 financial results. Investors will be invited to ask questions during the call, or they can submit questions prior to the conference call via the company's website at www.insitevision.com through the "Information Request" tab on the Investor Relations page.
Analysts and investors can participate in the conference call by dialing (877) 407-8035 for domestic callers and (201) 689-8035 for international callers. A telephone replay will be available following the conclusion of the call by dialing (877) 660-6853 for domestic callers and (201) 612-7415 for international callers. All callers will need to enter the account number 286 and conference ID 367633.
The live conference call will also be webcast and available on the Investor Relations page of the company's website at www.insitevision.com. A press release detailing fourth quarter and full year 2010 financial results will also be posted to the company's website and furnished to the Securities and Exchange Commission on a Form 8-K.
About InSite Vision
InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The company’s product portfolio utilizes InSite Vision’s proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Inspire Pharmaceuticals, and Besivance™ (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb and their partner Pfizer Inc. InSite Vision’s clinical-stage ophthalmic product pipeline includes ISV-502 and ISV-305 for the treatment of eye infections, ISV-303 for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit www.insitevision.com.
Louis Drapeau, 510-747-1220
Chief Financial Officer
Michelle Corral, 415-794-8662
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Biotechnology Optical Pharmaceutical